Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

Zydus Cadila Launches Generic Version of Remdesivir at Rs 2,800 Per Vial in India

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

Drug firm Zydus Cadila on Thursday said it had launched a generic version of Remdesivir, used for treating patients suffering from severe COVID-19 symptoms, at Rs 2,800 per 100 mg vial in the Indian market.

Branded as Remdac, the drug is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.

The company said the drug would be made available across India through the group’s distribution chain reaching out to government and private hospitals treating COVID-19 patients.

Remdac is the most affordable drug as we would like to enable patients to have access to this critical drug in the treatment of COVID-19,” Cadila Healthcare Managing Director Sharvil Patel said.

Through the course of this pandemic, the company’s efforts have been focused on supporting people in this healthcare crisis, whether it is through developing vaccines, ramping up production and distribution of critical drugs and therapies, making diagnostic tests available or exploring new treatment options, he added.

The drug’s active pharmaceutical ingredient (API) has been developed and manufactured at the group’s API manufacturing facilities in Gujarat, Zydus Cadila said.

It added that complete backward integration makes Remdac the most economical Remdesivir brand in India.

In June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences to manufacture and sell Remdesivir. This investigational drug has been issued an emergency use authorisation by the US Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of COVID-19, the filing said.

Zydus Cadila’s vaccine ZyCov-D is now in phase-II of clinical trials.

Zydus Cadila is the fifth company to have launched its generic version of Remdesivir in India. Hetero Labs, Cipla, Mylan and Jubilant Life Sciences have already launched their generic versions of antiviral drug Remdesivir in the country.

With a record single-day spike of 66,999 cases, India’s COVID-19 tally mounted to 23,96,637 on Thursday, according to the health ministry.

Shares of Cadila Healthcare, the listed entity of the Zydus group settled at Rs 385.90 per scrip on BSE, up 0.16 per cent from its previous close.

Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Join 10,000+ Fellow Readers

Get Techgenyz’s roundup delivered to your inbox curated with the most important for you that keeps you updated about the future tech, mobile, space, gaming, business and more.

Recomended

Find Apps

The Ultimate Hub for Discovering Apps Unlock a world of apps: your ultimate hub for exploring and discovering limitless possibilities for on your every needs.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic